Korean biotech HanAll Biopharma Co. Ltd. (KOSDAQ:009420) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize HL161 and HL036 in China, including Hong Kong and Macau, and Taiwan. HanAll retains rights elsewhere.